Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose PK comparison of subcutaneous mepolizumab delivery presentations in healthy subjects
2016-002405-19Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mepolizumab in asthma (3 arms), sponsored by GSK. Primary endpoints: Cmax, AUC(0-t) and 1 more. Started Dec 2016; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-002405-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002405-19.